Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02299141 · ClinicalTrials.gov registry record · Phase 2
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02299141 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 20 participants.
The verdict
NCT02299141, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
There has been limited benefit with angiogenesis inhibitor drugs in molecularly unselected patients in non-small cell lung cancer (NSCLC). The investigators propose that patients who are molecularly selected for treatment with nintedanib based on the presence of mutations in the following genes: VEGFR1-3, PDGFR-A, PDGFR-B, FGFR1-3, and TP53, will have clinically meaningful benefit in terms of response rate (RR) and progression-free survival (PFS). Furthermore the investigators plan to correlate outcomes with specific mutations and evaluate mechanisms of resistance.
Interventions
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-05-07 |
| Est. Completion | 2025-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02299141
The ClinicalTrials.gov registry entry for NCT02299141 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nintedanib is the first listed.
NCT02299141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02299141 about?
NCT02299141 is a clinical study titled "Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer". There has been limited benefit with angiogenesis inhibitor drugs in molecularly unselected patients in non-small cell lung cancer (NSCLC). The investigators propose that patients who are molecularly selected for treatment with nintedanib based on the presence of mutations in the following genes: VEG...
What is the current status of trial NCT02299141?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-05-07. Estimated completion is 2025-04-23.
What interventions are being tested in trial NCT02299141?
The interventions under investigation include: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT02299141?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.